

7-1-2020

CD4 Deficiency Causes Poliomyelitis and Axonal Blebbing in Murine Coronavirus-Induced Neuroinflammation.

Debanjana Chakravarty
Indian Institute of Science Education and Research

Fareeha Saadi
Indian Institute of Science Education and Research

Soumya Kundu
Indian Institute of Science Education and Research

Abhishek Bose
Indian Institute of Science Education and Research

Follow this and additional works at: <https://jdc.jefferson.edu/pacbfp>

Reas Khan
 University of Pennsylvania Sabeie Eye Institute

[Let us know how access to this document benefits you](#)

See next page for additional authors

Recommended Citation

Chakravarty, Debanjana; Saadi, Fareeha; Kundu, Soumya; Bose, Abhishek; Khan, Reas; Dine, Kimberly; Kenyon, Lawrence C; Shindler, Kenneth S; and Das Sarma, Jayasri, "CD4 Deficiency Causes Poliomyelitis and Axonal Blebbing in Murine Coronavirus-Induced Neuroinflammation." (2020). *Department of Pathology, Anatomy, and Cell Biology Faculty Papers*. Paper 299.
<https://jdc.jefferson.edu/pacbfp/299>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Pathology, Anatomy, and Cell Biology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors

Debanjana Chakravarty, Fareeha Saadi, Soumya Kundu, Abhishek Bose, Reas Khan, Kimberly Dine, Lawrence C Kenyon, Kenneth S Shindler, and Jayasri Das Sarma

1 **CD4 deficiency causes poliomyelitis and axonal blebbing in murine coronavirus induced**
2 **neuroinflammation**

3 Running title: CD4 T cells prevent poliomyelitis and axonal dystrophy

4 Debanjana Chakravarty^{1#}, Fareeha Saadi^{1#}, Soumya Kundu¹, Abhishek Bose¹, Reas Khan²,
5 Kimberly Dine², Lawrence C Kenyon³, Kenneth S Shindler^{2,4*} and Jayasri Das Sarma^{1,*}

6 ¹Department of Biological Sciences, Indian Institute of Science Education and Research
7 Kolkata, Mohanpur-741246, India

8 ²Departments of Ophthalmology and⁴Neurology University of Pennsylvania Scheie Eye
9 Institute, Philadelphia, PA 19104, USA

10 ³Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University,
11 Philadelphia, PA 19107, USA

12 **ABSTRACT:**

13 Mouse hepatitis virus (MHV) is a murine β -coronavirus (m-CoV) which causes a wide range
14 of diseases in mouse and rat, including hepatitis, enteritis, respiratory diseases, and
15 encephalomyelitis in the CNS. MHV infection in mice provides an efficient cause-effect
16 experimental model to understand the mechanisms of direct virus induced neural cell damage
17 leading to demyelination and axonal loss which are pathological features of Multiple sclerosis
18 (MS), the most common disabling neurological disease in young adults. Infiltration of T
19 lymphocytes, activation of microglia and their interplay are the primary pathophysiological
20 events leading to the disruption of myelin sheath in MS. However, there are emerging
21 evidences supporting gray matter involvement and degeneration in MS. The investigation of T
22 cell function in the pathogenesis of deep gray matter damage is necessary. Here, we employed
23 RSA59 (isogenic recombinant strain of MHV-A59) induced experimental neuroinflammation
24 model to compare the disease in CD4^{-/-} mice with CD4^{+/+} mice at days 5, 10, 15, and 30 p.i.
25 Viral titer estimation, nucleocapsid gene amplification and viral anti-nucleocapsid staining
26 confirm enhanced replication of the virions in the absence of functional CD4⁺ T cells in the
27 brain. Histopathological analyses showed an elevated susceptibility of CD4^{-/-} mice to axonal
28 degeneration in the CNS with augmented progression of acute poliomyelitis, and dorsal root
29 ganglionic inflammation rarely observed in CD4^{+/+} mice. Depletion of CD4⁺ T cells shows
30 unique pathological bulbar vacuolation in the brain parenchyma of infected mice with
31 persistent CD11b⁺ microglia/macrophages in the inflamed regions on day 30 p.i. In summary,

32 the current study suggests that CD4⁺ T cells are critical for controlling acute stage poliomyelitis
33 (gray matter inflammation) and chronic axonal degeneration, inflammatory demyelination due
34 to loss of protective anti-viral host immunity.

35 **#: Equal contribution**

36 Debanjana Chakravarty and Fareeha Saadi contributed equally to this work. Author order was
37 determined based on the relatedness of the work with Debanjana Chakravarty's PhD thesis.

38 *** Corresponding authors:**

39 Kenneth S. Shindler: Departments of Ophthalmology and Neurology, University of
40 Pennsylvania, Scheie Eye Institute, Philadelphia, PA 19104, USA. E-mail:
41 Kenneth.Shindler@uphs.upenn.edu

42 Jayasri Das Sarma: Department of Biological Sciences, Indian Institute of Science Education
43 and Research Kolkata, Mohanpur-741246, India. E-mail: dassarmaj@iiserkol.ac.in

44 **KEYWORDS:** CD4⁺T cells, Microglia, MHV infection, mCoV, Neuroinflammation, Innate
45 immune response, Demyelination, Host Immunity

46 **IMPORTANCE**

47 The current trend in CNS disease biology is to understand the neural cell-immune interaction
48 to investigate the underlying mechanism of neuroinflammation, rather than focusing on
49 peripheral immune activation. Most studies in MS are targeted toward understanding the
50 involvement of CNS white matter. However, the importance of gray matter damage has become
51 critical in understanding the long-term progressive neurological disorder. Our study highlights
52 the importance of CD4⁺T cells in safeguarding the neurons against axonal blebbing and
53 poliomyelitis from murine Betacoronavirus-induced neuroinflammation. Current knowledge
54 of the mechanisms that lead to gray matter damage in MS is limited, because the most widely
55 used animal model EAE does not present this aspect of the disease. Our results thus, add to the
56 existing limited knowledge in the field. We also show that the microglia, though important for
57 the initiation of neuroinflammation, cannot establish a protective host immune response
58 without the help of CD4⁺ T cells.

59 **INTRODUCTION**

60 Neuroinflammation is the cardinal signature of several complex and multi-faceted central
61 nervous system (CNS) disorders. CNS inflammation is known to be initiated mainly by the
62 brain's resident innate immune cells, the microglia, which rapidly respond to an infectious
63 agent or any perturbation in the CNS. Via the secretion of chemokines and cytokines, they
64 direct the extravasation of several myeloid cells, including neutrophils,
65 monocytes/macrophages, and dendritic cells, which in turn promote the entry and activation of
66 adaptive immune responsive T cell populations into the CNS(1-4).

67 Regulation of T cells is central to understanding the cellular and humoral immunity in
68 neuroinflammation. So far, most studies have demonstrated the destructive pathogenic effects
69 of encephalitogenic T cells in neurodegeneration. For example, Multiple sclerosis (MS the
70 most common neurological disease of young adults is characterized predominantly by self-
71 reactive myelinolytic T cell-mediated autoimmune destruction of the myelin sheath (5-10).
72 Likewise, in an experimental animal model of MS, Experimental autoimmune
73 encephalomyelitis (EAE), the disease mainly depends on the infiltration of pathogenic CD4⁺ T
74 cells, which are primarily of Th1 and Th17 types (11-19). Studies have also shown a pathogenic
75 role of myelin-specific CD8⁺ T cells in the inflammatory lesions in EAE mice brains (20-22).
76 A Mouse hepatitis virus (MHV) (V5A13.1) model of induced neuroinflammation showed a
77 significant reduction in the severity of inflammation and demyelination in CD4^{-/-} mice at days
78 12-21 p.i. compared to both CD8^{-/-} and wild type mice (23). Adoptive transfer of CD4⁺T cells
79 and CD8⁺T enriched splenocytes differentially affect the state of inflammation and
80 demyelination in MHV-JHM infected RAG^{-/-} mice and induction of donor splenocytes with a
81 depleted population of both CD4 and CD8⁺ T cells in JHM infected RAG^{-/-} mice prevents
82 demyelination (24). However, recent advances have shown that the prevalence of activated
83 adaptive immune responses are not restricted to neuroinflammatory myelin degeneration as
84 seen in MS but translates across classic neurodegenerative disorders such as Alzheimer's
85 disease (AD), Parkinson's disease (PD) and Amyotrophic lateral sclerosis (ALS) (25, 26) (27,
86 28) (29) (30).

87 With the shift in the paradigm of CNS immunology and the discovery of CNS meningeal
88 lymphatic vessels, several studies also suggested that CD4⁺ T cells may provide protective
89 immunity against cognitive and motor disabilities in neurodegenerative disorders (31) (32).
90 Activated CD4⁺ T cells also help in limiting MHV-JHM replication within the CNS (33). Either
91 CD4 or CD8 deletion in Theiler's Murine Encephalomyelitis (TMEV) resistant B6 strain

92 makes the mice susceptible to disease and shows increased viral persistence and demyelination
93 (34). The current research trend is thus targeted toward understanding the differential
94 mechanisms that regulate the balance between neuroprotection and neurodestruction conferred
95 by CD4⁺ T cells.

96 Several studies have demonstrated the accumulation of microglia/macrophages in the vicinity
97 of reactive CD4⁺ T cells in CNS lesions during neurodegeneration (4, 30, 35-37). While ample
98 literature supports CD4⁺ T cells interaction with CNS resident microglia and/or infiltrating
99 myeloid-specific monocytes/macrophages as the primary mechanisms underlying white matter
100 damage in the early relapsing-remitting stage of MS, one cannot overlook their function behind
101 immune mediated grey matter atrophy.

102 The current study is focused on understanding the potential protective role of CD4⁺ T cells on
103 microglial activation and their cooperative effect on both white and gray matter damage
104 following infection with a neurotropic isogenic spike protein recombinant strain of
105 Betacoronavirus MHV, RSA59. Intracranial infection of C57BL/6 mice with RSA59 results in
106 a biphasic disease, characterized by acute hepatitis and meningoencephalomyelitis followed by
107 chronic immune-mediated demyelination and concomitant axonal loss, which mimics specific
108 pathologies of the human demyelinating disease MS (38-40). RSA59 induced acute
109 neuroinflammation comprises mixed populations of astrocytes and inflammatory cells, mainly
110 microglia/macrophages and a smaller population of T lymphocytes (40-44). As early as day 3
111 post-infection (p.i.), peripheral leukocytes start to infiltrate the CNS, beginning with the cells
112 of the innate immune response predominantly myeloid cells such as neutrophils and
113 monocytes/macrophages. Lymphoid cells, including CD4, CD8, and NK T cells start to appear
114 in the CNS at day 5 p.i. and their infiltration peaks at day 7 p.i. followed by the start of viral
115 clearance (Fig. 1). While CD8⁺ T cells begin to disappear as early as day 10 p.i. and NK T cells
116 reduce in number, a significant number of CD4⁺ T cells are present in the inflamed brain even
117 at day 16 p.i. (Fig. 1). While inflammation resolves and infectious virus particles clear from
118 the brain, Iba1⁺ macrophages/microglia persist significantly within the demyelinating plaques
119 in the spinal cord white matter and are known to cause direct myelin stripping (40). Recent
120 Affymetrix microarray analysis in the spinal cord of RSA59 infected mice showed elevated
121 expression of inflammatory mediators during the acute stage of infection. Interestingly,
122 conventional T and B cell markers showed no or insignificant upregulation (45, 46). Expression
123 of adaptive immune responsive genes showed prominent upregulation during the chronic phase

124 (46). The most striking associations were observed between CD3, CD45, and MHCII
125 expression, which promote the communication between innate and adaptive immune systems
126 via microglia-CD4⁺T cell signalling.

127 Current study employs a CD4 knock out strain in the background of C57BL/6 mice (CD4^{-/-}).
128 In comparison to the wild type C57BL/6 mice (CD4^{+/+}), infection of CD4^{-/-} mice produces an
129 exaggerated disease course in association with enhanced viral replication and prolonged viral
130 persistence. Moreover, CD4^{-/-} mice are more susceptible to chronic inflammation, and axonal
131 degeneration compared to CD4^{+/+} mice, and CD11b⁺ macrophages/microglia show persistent
132 activation even during the chronic disease phase. Our results suggest a novel neuroprotective
133 role of CD4⁺ T cells in the MHV induced demyelinating model of MS unlike the EAE model
134 where T cells have a predominantly pathogenic role.

135 **RESULTS**

136 Mice were inoculated with isogenic EGFP expressing RSA59 as described in the materials and
137 methods section. Experimental mice were monitored daily for the development of clinical
138 signs and symptoms. The majority of CD4^{+/+} mice displayed low disease scores ranging from
139 0.5 to 1, indicated by ruffled fur and occasionally present the hunch back phenotype as
140 observed previously (47). 100 % mice survived until day 30 p.i as observed . Though not
141 significantly different, CD4^{-/-} mice showed a slightly higher disease score of 1.5 to 2 indicated
142 by hind limb weakness in addition to hunch back, the symptoms started appearing as early as
143 day 3-5 p.i., however, almost 90% mice survived until day 30 p.i. The scoring system has been
144 discussed in the materials and methods section.

145 **The absence of functional CD4⁺ T cells does not alter acute stage hepatitis and**
146 **meningoencephalomyelitis but shows gray matter involvement in the form of**
147 **poliomyelitis and Dorsal Root Ganglion inflammation.**

148 The current study initially investigated differences in phenotypic or pathological symptoms as
149 well as basal level of inflammation at the tissue level between mock infected CD4^{+/+} and CD4^{-/-}
150 ^{-/-} mice. No significant differences were observed at the phenotypic level. Conventional light
151 microscopy data analysis at H& E staining sections from liver, brain and spinal cord revealed
152 that mock infected (MI) CD4^{+/+} and CD4^{-/-} mice presented only a basal level of inflammation
153 (if any) in all the three tissue types (Fig 2). Mock infected CD4^{-/-} mice did not show any

154 differential phenotypic or histopathological features concerned for this study. All experiments
155 were conducted using age matched CD4^{+/+} and CD4^{-/-} mice.

156 To examine the degree of inflammation in CNS and non-CNS tissues, MI and infected CD4^{+/+}
157 and CD4^{-/-} mice were sacrificed at two-time points, day 5-6 p.i. (onset of the peak of
158 neuroinflammation) and day 30 p.i. (chronic phase of inflammation). The liver, brain, and
159 spinal cord tissues were harvested and fixed in 4 % paraformaldehyde and paraffin embedded.

160 During the acute phase of infection, comparable, multiple foci of moderate to severe
161 necrotizing, and non-necrotizing hepatitis were observed in both CD4^{+/+} and CD4^{-/-} mice (Fig.
162 3a). During the chronic phase, hepatitis nearly resolved, but the number of remnant hepatic
163 lesions were more in CD4^{-/-} mice (Fig. 3b). The Hepatic Activity Index showed no significant
164 difference at day 6 and 30 p.i. between CD4^{+/+} and CD4^{-/-} mice (Fig. 3b).

165 H&E stained brain sections from RSA59 infected CD4^{+/+} and CD4^{-/-} (Fig. 4a) mice
166 demonstrated focal acute encephalitis, meningitis, intra-parenchymal perivascular lymphocytic
167 cuffing, and microglial nodule formation at the acute phase of infection. Corresponding serial
168 brain sections immunohistochemically stained with anti-CD45 (leukocyte common antigen,
169 LCA) confirmed similar levels of inflammatory cells in the brain parenchyma of CD4^{+/+} (2.691
170 ± 0.4561) and CD4^{-/-} (2.485 ± 0.3849) mice(48). H&E staining of both CD4^{+/+} and CD4^{-/-} (Fig.
171 4b) infected spinal cords showed myelitis. Quantification of the staining intensity suggests that
172 corresponding regions were equally immunoreactive for CD45, indicating the comparable
173 infiltration of mononuclear cells in CD4^{+/+} (1.176 ± 0.1958) and CD4^{-/-} mice (1.355 ± 0.1947).
174 However, the consequent anti-CD11b (pan-macrophage marker) immunohistochemistry
175 revealed significantly fewer macrophage/microglia in the brains and spinal cords of CD4^{-/-}
176 mice (0.6067 ± 0.1260 , **** $p < 0.0001$ and 0.258 ± 0.07078 , ** $p < 0.01$ respectively), as
177 compared to CD4^{+/+} mice (4.749 ± 0.3981 , and 1.110 ± 0.3007 , respectively) (Fig. 5).
178 Moreover, apart from the white matter myelitis in both infected CD4^{+/+} and CD4^{-/-} mice, CD4^{-/-}
179 mice showed evidence of acute poliomyelitis (gray matter inflammation) and dorsal root
180 ganglionic inflammation which were rarely observed in CD4^{+/+} mice at the acute phase of
181 infection (Fig. 6). Average inflammation scores, based on H&E, are shown in Table I and II.

182 **The absence of CD4⁺ T cells impairs RSA59 clearance from the brain tissue.**

183 To assess the role of CD4⁺ T cells in virus clearance, viral titer, viral nucleocapsid gene
184 amplification, in situ viral antigen distribution and mRNA level of anti-viral pro-inflammatory
185 cytokines /chemokines were evaluated.

186 RSA59 titer kinetics was compared in the brains of CD4^{-/-} and CD4^{+/+} mice, and the values
187 were expressed as log₁₀ PFU/ gram of tissue. In both mouse strains, the virus replicated
188 efficiently in the brain at day 5 p.i. (10^{5.8} PFU/gm in CD4^{-/-} versus 10^{6.1} PFU/gm in CD4^{+/+}).
189 By day 10 p.i. CD4^{-/-} mice averaged almost 1-log-higher viral titre (10⁵ PFU/gm versus 10^{3.9}
190 PFU/gm, *p= 0.016) than CD4^{+/+} mice. On day 15 p.i. there were no detectable viral PFUs in
191 CD4^{+/+} mice, however, a significant number of infectious viral PFUs were observed in CD4^{-/-}
192 mice (10^{4.6} PFU/gm, ****p=0.0001) (Fig. 7a).

193 To further confirm whether differences in viral replication might affect viral infection, qRT-
194 PCR of viral N-gene (nucleocapsid) from brain tissues from MI, CD4^{+/+}, and CD4^{-/-} infected
195 mice was performed. As shown in Fig. 7b, viral persistence is comparable in both CD4^{+/+} and
196 CD4^{-/-} mice (1.02 fold ± 0.176) at day 5 p.i. At day 10 and day 15 p.i., the N-gene transcript
197 shows significant upregulation (10.230 folds ± 2.677, **p= 0.003 and 23.247 folds ± 5.204,
198 ****p< 0.0001, respectively), in CD4^{-/-} mice compared to CD4^{+/+}.

199 To determine the spread of infectious viral particles in situ, immunohistochemical analysis of
200 viral anti-nucleocapsid antigen was performed on sections of infected brains obtained from
201 CD4^{+/+}, CD4^{-/-}, and MI mice at the acute and chronic phases of infection. In MI mice, viral
202 antigen was neither observed at day 6 nor at day 30 p.i. as expected (Fig. 7c). Post-intra-cranial
203 inoculation, RSA59 replicates profusely in CD4^{+/+} mice and spreads rapidly from the lateral
204 geniculate nuclei to several regions of the brain, including the olfactory bulb, basal forebrain,
205 cerebral cortex, anterior commissure, brain stem and deep cerebellar white matter. By day 6
206 p.i., viral antigen becomes restricted to the midbrain, pons, and deep cerebellar white matter in
207 the current study (data not shown). Similar viral anti-nucleocapsid antigen staining was
208 observed in infected CD4^{-/-} mice at day 6 p.i. Day 30 post infected brains of CD4^{+/+} mice
209 showed significantly reduced viral antigen staining as expected, whereas a considerable
210 number of cells remained positive for viral anti-nucleocapsid antigen in the CD4^{-/-} mice (Fig.
211 7c).

212 Moreover, Interferon gamma (IFN-γ) mRNA expression was significantly higher at day 5 p.i.
213 in CD4^{-/-} mice (2.45 folds ± 0.59, **p=0.0020), Fig. 7d, in comparison to CD4^{+/+} mice,

214 indicating higher viral replication in CD4^{-/-} mice. Similarly, peripheral leukocyte
215 chemoattractant IFN- γ inducible CXCL10 (a C-X-C chemokine) mRNA expression remained
216 significantly upregulated even at day 10 p.i. (5.102 folds \pm 1.253, ***p=0.0008) and day 15
217 p.i. (2.965 folds \pm 0.858, *p=0.015) in the infected CD4^{-/-} mice (Fig. 7e) as compared to CD4^{+/+}
218 mice. Also, anti-viral Tumour Necrosis Factor alpha (TNF- α) mRNA expression was observed
219 to be significantly upregulated at all time points in CD4^{-/-} mice, in comparison to CD4^{+/+} mice
220 (6.372 folds \pm 1.10, ****p<0.0001 at day5, 37.949 folds \pm 9.534, ****p=0.00018 at day 10,
221 and 7.348 folds \pm 1.675, ****p<0.0001 at day 15), Fig. 7f. At the same time, CD4^{-/-} mice
222 displayed lower levels of RANTES (Regulated upon Activation, Normal T Cell Expressed and
223 Presumably Secreted) or CCL5 (a C-C chemokine, involved in trafficking of
224 macrophage/monocytes into the CNS) mRNA transcripts at day 5 p.i. (0.523 folds \pm 0.124,
225 **p<0.01 and day 10 p.i. (0.544 folds \pm 0.214, *p<0.05) in comparison to CD4^{+/+} mice (Fig.
226 7g)

227 Viral plaque assays and qRT-PCR of viral N-gene and antiviral-cytokines and chemokines
228 expression (IFN- γ , TNF- α , CXCL10) at day 5, 10 and 15 p.i in corroboration with the viral
229 anti-nucleocapsid antigen staining at day 30 p.i. confirmed prolonged persistence of RSA59
230 in the absence of functional CD4 in brain tissue.

231 **The absence of CD4⁺ T cells exacerbates CNS inflammation and myelin loss at the chronic** 232 **stage of inflammation.**

233 The role of functional CD4⁺ T cells in demyelination was next examined by histopathological
234 analysis of day 30 post-infected spinal cords from CD4^{+/+} and CD4^{-/-} mice. In CD4^{+/+} mice,
235 inflammation was observed in the dorsal/posterior columns, anterior horn and/or the lateral
236 descending tracts. H&E staining highlights the inflammation in the ventrolateral white matter.
237 In contrast, CD4^{-/-} mice demonstrated vacuolar pathology with swollen axons throughout the
238 white matter, involving the ventral and lateral descending tracts upon H& E staining (Fig. 8a).
239 Corresponding inflamed regions from serial sections also showed myelin loss by LFB staining
240 in both CD4^{+/+} and CD4^{-/-} mice. The degree of demyelination was significantly higher in the
241 CD4^{-/-} mice (20.45 \pm 2.174, ****p<0.0001) compared to CD4^{+/+} mice (6.008 \pm 1.375) (48)
242 (Fig. 8b). CD45 immunoreactive inflammatory cells were present within the demyelinating
243 plaques in both CD4^{+/+} and CD4^{-/-}, however the extent of inflammation was considerably
244 greater in CD4^{-/-} (2.812 \pm 0.1122, ****p<0.0001) mice in comparison to the CD4^{+/+} mice
245 (0.5509 \pm 0.08550) (Fig. 8c). Interestingly, in contrast to the acute phase of infection, CD4^{-/-}

246 mice (1.237 ± 0.1646 , $***p < 0.001$) spinal cord showed highly significant CD11b
247 microglia/macrophage expression, in comparison to CD4^{+/+} mice (0.4175 ± 0.09144). (Fig. 8d)

248 Quite strikingly, in contrast to the brains of CD4^{+/+} (Fig. 9a) mice, CD4^{-/-} mice exhibited
249 extensive vacuolation in the brain stem and the deep cerebellar white matter tracts which has
250 not been observed in previous studies. No significant differences were observed in CD45
251 staining between the two groups (Fig. 9b). Large numbers of CD11b positive
252 microglia/macrophages were observed in the vicinity of the vacuolated regions in CD4^{-/-} mice
253 (5.251 ± 0.5298 , $****p < 0.0001$) as compared to CD4^{+/+} mice (2.220 ± 0.1639) (Fig. 9c).

254 **The Absence of CD4⁺ T cells aggravates axonopathy**

255 One-micron thick sections of glutaraldehyde fixed brains and spinal cords from RSA59
256 infected CD4^{-/-}, CD4^{+/+}, and MI CD4^{-/-} mice were stained with toluidine blue. MI CD4^{-/-} did
257 not show any visible signs of inflammation (Fig. 10) or spinal cord damage. Infected CD4^{-/-}
258 mice exhibited vacuolation and axonal degeneration in the posterior columns (Fig. 11a, b).
259 Electron microscopy of the vacuolated brainstem lesions in CD4^{-/-} mice revealed that the
260 vacuolation represents numerous swollen degenerating axons, and few inflammatory cells
261 (lymphocytes and macrophages). There was no evidence of isolated demyelination (myelin
262 loss with relative axonal preservation) (data not shown). Similarly, electron micrographs of the
263 spinal cord white matter lesions (Fig. 11c, d) also showed axonal degeneration and a lack of
264 demyelination. No inflammatory cells (lymphocytes and macrophages) were present within the
265 areas of white matter damage (Fig. 11c).

266 **In the absence of CD4⁺ T cells, mice show differential expression of inflammatory** 267 **cytokines.**

268 The inflammatory cells in the demyelinating lesions induced by RSA59, exhibit variable
269 expression of pro- and anti-inflammatory cytokines. Expression of pro-inflammatory IL-6, IL-
270 12p40, and anti-inflammatory IL-10 were examined in RSA59 infected mouse brains.
271 Quantitative PCR results revealed that IL-6 expression was significantly higher in CD4^{-/-}
272 compared to CD4^{+/+} mice both at day 5 (6.742 folds ± 1.955 , $****p < 0.0001$) and day 10 p.i.
273 (4.24 folds ± 0.912 , $****p < 0.0001$), and subsequently declines at day 15 p.i. in both groups of
274 mice (Fig. 12a). IL-10 expression patterns, as revealed by real-time PCR, showed similar
275 expression in the RSA59 infected CD4^{+/+} and CD4^{-/-} mice at day 5 p.i. However, at days 10
276 (2.579 folds ± 0.72 , $**p = 0.003$) and 15 p.i. (2.58 folds ± 0.363 , $****p < 0.0001$) CD4^{+/+} mice

277 showed significantly elevated expression of IL-10 compared to infected CD4^{-/-} mice (Fig. 12b).
278 IL-12p40 mRNA expression demonstrated no considerable differences between CD4^{+/+} and
279 CD4^{-/-} mice following RSA59 infection (data not shown). Together the expression patterns of
280 IL-6 and IL-10 indicate a robust inflammatory environment in the brains of CD4^{-/-} mice.

281 **The absence of CD4⁺ T cells influences macrophage polarization.**

282 Using the classical M1/M2 nomenclature of macrophage polarization, it was observed that
283 mRNA expression of classical M1 macrophage (pro-inflammatory) markers such as CD86
284 and Bruton's tyrosine kinase (Btk) were significantly reduced in infected CD4^{-/-} mice in
285 comparison to CD4^{+/+} mice at day 5 p.i (0.445 folds \pm 0.128, ***p<0.001 and 0.545 folds \pm
286 0.134, **p<0.01, for CD86 and Btk respectively) (Fig. 12c.d). But, as the course of disease
287 progressed toward the chronic phase, microglia/macrophages in the infected CD4^{-/-} mice
288 showed an M2 phenotype (anti-inflammatory) in contrast to the CD4^{+/+} mice, as observed by
289 the significant upregulation in the mRNA expression of M2 macrophage marker CD163 at day
290 15 p.i. (2.018 folds \pm 0.392, ****p<0.0001) (Fig. 12e).

291 **DISCUSSION**

292 The CNS is no longer considered an immune-privileged site (49). A significant number of
293 peripheral CD4⁺ T cells patrol the cerebrospinal fluid (CSF) in order to detect the presence of
294 potential harmful pathogens (50-52). If these T cells do not encounter their cognate antigen,
295 they take the lymphatic route to exit the CNS. However, they will infiltrate the CNS
296 parenchyma upon sensing any sign of neuroinflammation (52, 53). MHV infection in mice is
297 an established archetype animal model used to understand the demyelination pathology in MS.
298 In this study, we present a protective role of CD4⁺ T cells in the viral induced
299 neuroinflammatory demyelination, in contrast to the pathogenic role of CD4⁺T cells in MS(54)
300 and its autoimmune experimental model EAE. Activated myelinolytic CD4⁺ T cells have been
301 observed in the blood and cerebrospinal fluid (CSF) of MS patients (7); Additionally, MS
302 lesions have been widely associated with the presence of both CD4⁺ and CD8⁺ T cells
303 (55).These autoreactive T cells induce a Th-1 response, majorly targeted against PLP, and can
304 worsen the disease progression in the patients (56-58). Considering their well-
305 accepted pathogenic role in MS, classical immuno therapies are devised to silence the CD4⁺ T
306 cell mediated attack on the myelin to repair the damage caused to the myelin sheath. Our study

307 highlights a quite opposite, protective role of CD4⁺T cells in a virus induced etiology of
308 demyelination in MS.

309 In this study, we present evidences to show that spatio-temporal infiltration of CD4⁺ T cells in
310 the CNS and their dynamic equilibrium with brain resident microglia may influence the
311 progression, severity, and amelioration of white and gray matter inflammation in a neurotropic
312 virus model. The most widely used experimental model of MS, EAE, holds good only for
313 understanding the mechanisms of white matter injury and does not recapitulate the aspects of
314 gray matter damage.

315 The RSA59-induced demyelinating model is unique, it involves both white and gray matter
316 inflammation. The onset of the disease is initiated via orchestration of innate immune genes in
317 the acute phase to clear the virus and restore homeostasis and then gradually progress via
318 adaptive immunity during the chronic phase (45). RSA59 induced demyelination is dissimilar
319 to other conventional demyelinating models that are explicitly driven by adaptive immune
320 responses, with its array of specialized T cells (CD4⁺ and CD8⁺) and myelin antigen-specific
321 antibodies (20, 59, 60). Dynamic host immune responses involving CD4⁺ helper T cells are
322 needed for recovery from infections. While CD4⁺ T cells are helpers for the development of a
323 complete adaptive immune response, they are also required for enhancing innate immune
324 effector functions. To assess the role of CD4⁺ T cells in the innate and adaptive immune
325 responses and their interactions with microglia/macrophages following RSA59 infection, the
326 current study compared CD4^{-/-} mice and wild-type mice. The results showed a critical role of
327 CD4⁺ T cells in the pathogenesis of RSA59 induced neuroinflammation. We observed the
328 following: i) Absence of CD4⁺ T cells caused no change in acute encephalitis; but CD4^{-/-} mice
329 showed a significant reduction in CD11b positive microglia/macrophages; ii) viral replication
330 was higher and viral transcripts were persistent in CD4^{-/-} mice, even at day 30 p.i.; iii) CD4^{-/-}
331 mice showed an augmented susceptibility toward chronic phase encephalitis and
332 demyelination. Furthermore, CD4^{-/-} mice, presented with poliomyelitis, bulbar (brainstem)
333 vacuolation of the neuropil, and dorsal root ganglionic inflammation, a finding rarely observed
334 in CD4^{+/+} mice; iv) a strikingly higher number of CD11b positive microglia/macrophages were
335 present in the CD4^{-/-} mice at the chronic infection phase. These microglia/macrophages were
336 disseminated throughout the inflamed regions of white matter and in the areas of gray matter,
337 both in the brain and spinal cord at the chronic infection phase; and v) Electron microscopy
338 revealed axonal degeneration in the spinal cords of CD4^{-/-} mice even in the absence of

339 inflammation, suggesting that white matter degeneration occurs secondary to neuronal injury
340 without a direct attack of inflammatory cells upon spinal cord myelin sheaths.

341 Our results also revealed substantially higher mRNA expression levels of IFN γ , TNF α , and
342 IFN inducible leukocyte chemoattractant CXCL10 in the CD4^{-/-} mice in comparison to CD4^{+/+}
343 mice which is likely a response to recruit further peripheral lymphocytes into the CNS to
344 combat the persistent viral load in the former. The increased and uncontrolled viral replication
345 contributes to severe inflammation and neuronal cell body damage observed in the gray matter
346 of the spinal cord and dorsal root ganglion of the CD4^{-/-} mice. Elevated mRNA levels of pro-
347 inflammatory cytokine IL-6 at day 5 and 10 p.i. along with persistent viral load signifies a
348 robust pro-inflammatory environment in the CNS of CD4^{-/-} mice. Expression of the anti-
349 inflammatory cytokine IL-10 remains almost constant throughout the study in CD4^{+/+} mice,
350 while its expression in CD4^{-/-} is consistently low, suggesting that CD4⁺ T cells serve as one of
351 the key sources of IL-10 production.

352 Apart from this, it was interesting to note that anti-viral chemokine CCL5 or RANTES
353 (macrophage/monocyte chemoattractant) was downregulated in CD4^{-/-} mice at day 5 and 10
354 p.i., perhaps as a result of which a significant reduction in CD11b positive inflammatory cells
355 was observed in the brains and spinal cords at the acute phase of inflammation. Nevertheless,
356 overall encephalitis at the acute phase, as shown by CD45 staining, was comparable in both
357 CD4^{+/+} and CD4^{-/-} mice, suggesting that the initial inflammation in the CNS is independent of
358 CD4⁺ T cells. This finding also hints that the fewer numbers of CD11b⁺ cells might be the
359 result of dampened infiltration of monocyte/macrophages in the absence of functional CD4⁺ T
360 cells and the CD11b⁺ cells observed in the CNS might correspond to the brain resident
361 microglia.

362 The function and role of microglia as mediators of homeostasis in the CNS is well established
363 (61). They not only act as custodians of CNS immunity but also protect neurons during
364 development and monitor synaptogenesis (62). However, during pathological conditions,
365 microglia attain a signature pro-inflammatory state that is directed toward the clearance of toxic
366 substances from the CNS (63, 64). M1 or classically activated microglia can also induce the
367 activation of A1 astrocytes, which develop altered ability to promote neuroprotection (65). A2
368 astrocytes are activated by M2 microglia (alternatively activated) and help in CNS repair and
369 protection (66). Examination of mRNA expression revealed a higher expression of pro-
370 inflammatory M1 markers CD86 and Btk in the CNS of CD4^{+/+} mice during the acute infection.

371 CD163 mRNA transcripts increased in expression in the CD4^{+/+} mice during day 10 p.i. and
372 then declined with the restoration of homeostasis, but CD4^{-/-} mice showed a significant increase
373 in the expression of CD163 mRNA even at day 15 p.i. suggesting that the CD11b⁺
374 microglia/macrophages present during the transition phase (from acute to chronic) in the CNS
375 might be of the M2 phenotype (anti-inflammatory) attempting to combat the prolonged viral
376 persistence and restore homeostasis to prevent further tissue damage, but fail to do so without
377 the help of CD4⁺T cells. Though M2 microglia/macrophages are categorized as anti-
378 inflammatory, they are also reported to have high phagocytic ability. Their activation and
379 persistence might, therefore, promote direct myelin stripping as previously reported (40)
380 leading to significantly greater demyelination and axonal loss in the CD4^{-/-} mice.

381 An interesting question that remains to be answered is if the infiltration of
382 monocyte/macrophages is impeded in the first place, why is there a higher expression of CD11b
383 positive cells in the CNS of CD4^{-/-} mice during the chronic phase? To answer this, future
384 experiments are aimed at performing immunophenotyping of the inflammatory cells, using
385 flow cytometry in the CD4^{-/-} mice, to explicitly decipher whether the cells present at the chronic
386 phase are predominately peripherally recruited monocytes/macrophages or the activated
387 resident phagocytic microglial cells of the CNS. So far, flow cytometric analysis in CD4^{+/+}
388 mice has shown the presence of a significant population of CD11b^{hi}/CD45^{lo} (microglia) at
389 day 30 p.i. but very little or no CD11b expressing CD45^{high} monocyte/macrophages in the
390 CNS (data not shown). We, therefore, expect the CD11b⁺ cells found in the CNS at day 30 in
391 the CD4^{-/-} mice to be microglia and not peripherally recruited myeloid cells.

392 For this study, we have opted for a mouse strain (B6.129S2-Cd4^{tm1Mak/J}) where the
393 functionality of CD4⁺ T helper cells was disrupted. The development of CD8⁺ T cell and
394 myeloid components was unaffected. 90% of the circulating T cells were CD8⁺ and their
395 cytotoxic activity was within normal ranges (67). Despite the presence of functional CD8⁺ T
396 cells, viral clearance was substantially delayed. Thus, our studies suggest a vast preponderance
397 of CD4⁺ T cells over CD8⁺ T cells in maintaining the homeostasis upon RSA59 induced
398 neuroinflammation.

399 In conclusion, our results demonstrate that CD4⁺ T cells are necessary for eliminating viral
400 particles, promoting microglial polarization toward anti-inflammation, and controlling chronic
401 progressive axonal degeneration. The current study also highlights the importance of CD4⁺T
402 cells beyond the classic inflammatory lesions of the white matter tract. We have shown that

403 gray matter inflammation in the form of poliomyelitis is significantly exacerbated in the
404 absence of CD4⁺ T cells. Moreover, we show that the imprinting of the microglia/macrophage-
405 mediated inflammatory innate immune response on the consequent protective adaptive
406 immunity requires functional CD4⁺ T cells. This communication between microglia and T cells
407 is a highly regulated, interdependent, and bidirectional process and is critical for the
408 establishment of an effective immune response. Although innate anti-viral immune responses
409 by microglia are crucial in controlling the initial CNS viral dissemination, virus-specific T cells
410 are essential to eliminate the virus and provide indispensable neuroprotection. Further studies
411 will be conducted to understand the nexus between CNS resident microglia/monocyte-derived
412 macrophages with infiltrating activated T helper cells at the molecular level through immune-
413 coregulatory CD40-CD40 ligand (L) pathway. This dyad is broadly recognized for its essential
414 role in immune regulation and homeostasis. Our studies will be focused to examine such
415 interactions at the molecular level using CD40 and CD40L deficient mice in the outcome of
416 inflammatory demyelination. Most MS therapies are aimed at preventing damage to myelin by
417 regulating the multiple components of adaptive immune system, especially the T cell subsets
418 (Th1, Th2, Th17, CD8⁺, NKT, CD4⁺CD25⁺ T regulatory cells) and B cells. Current therapies
419 have only been able to reduce the number and rate of MS lesion formation and are only partially
420 efficacious(68). Understanding the role of T cells in a viral induced model of MS is thus critical
421 to design more robust therapeutics. Together these studies can help to expand our knowledge
422 intended to use CD4 mediated immune therapy as a potential treatment of MS, depending on
423 its etiology and the initiation of the pathology.

424 **MATERIALS AND METHODS**

425 **Virus, Inoculation of mice and Experimental design**

426 Recombinant isogenic demyelinating (DM) strain of MHV-A59, RSA59, was used to infect
427 mice as formerly described (39). Four to five-week old, MHV-free, CD4^{+/+/+} C57BL/6 (B6)
428 mice (Jackson Laboratory) and CD4^{-/-} (B6.129S2-Cd4^{tm1Mak/J}) mice (Jackson Laboratory,
429 Stock no. 002663) were used for the study. The CD4^{-/-} mice obtained from Jackson's laboratory
430 is homozygous for the Cd4^{tm1Mak} targeted mutation, have a significant blockade in the CD4⁺ T-
431 cell development and show an MHC class II restricted T helper cell activity(67). The mice
432 were inoculated intracranially with 25,000 (50% of LD50) PFU of RSA59 strain as described
433 previously. Likewise, mock-infected controls for CD4^{+/+} and CD4^{-/-} mice were inoculated
434 with an uninfected cell lysate (PBS+0.075% BSA) at an equivalent dilution. Mice were

435 monitored daily post infection (p.i.) for disease signs and symptoms. Clinical disease severity
436 was graded using the following scale: 0, no disease symptoms; 1, ruffled fur; 1.5, hunched back
437 with mild ataxia; 2, Ataxia, balance problem and hind limb weakness; 2.5 one leg completely
438 paralyzed, motility issue but still able to move around with difficulties; 3, severe
439 hunching/wasting/both hind limb paralysis and mobility is severely compromised;3.5 Severe
440 distress, complete paralysis and moribund 4, dead (47).

441 For EM, histopathological, and immunohistochemical analyses mice were sacrificed at the
442 acute infection phase, i.e. on day 5-6 (four mice per group), and chronic infection phase, i.e.
443 day 30 (five mice per group) post-infection. For RNA and protein studies and viral titer
444 estimation, animals were sacrificed (3 mice per group) on days 5, 10 and 15 post-infection.

445 **Estimation of Viral Replication**

446 Mice were euthanized on days 5, 10 and 15 post-infection and perfused transcardially with 20
447 ml of sterile PBS. Brains were harvested for determination of viral titers and placed into 1 ml
448 of isotonic saline containing 0.167% gelatin (gel saline). Brain tissues were weighed and kept
449 frozen at -80°C until titred. Tissues were subsequently homogenized, and viral titers were
450 quantified by standard plaque assay protocol on tight monolayers of L2 cells as described
451 previously with minor modifications (39).

452 **Histopathology and Immunohistochemical Analysis**

453 Mice were sacrificed at day 6 and day 30 post-infection. Following transcardial perfusion with
454 PBS and 4% paraformaldehyde, liver, brain, and spinal cord tissues were harvested and
455 embedded in paraffin. Five-micron thick sections of the embedded tissues were prepared and
456 stained with Hematoxylin and Eosin for histopathologic analysis. Luxol fast blue (LFB)
457 staining was performed to evaluate demyelination in the brain and spinal cord tissues, as
458 described previously with minor modifications (40).

459 Immunohistochemical staining of brain and spinal cord tissue sections used the following
460 primary antibodies - 1:10000 dilution of anti-CD11b (Abcam, Cat #:ab133357), 1:200 dilution
461 of anti-CD45 (LCA; leukocyte common antigen, BD Pharmingen Cat#:550539) and 1:40
462 dilution of monoclonal antibody directed against the nucleocapsid protein (N) of MHV
463 (monoclonal antibody clone 1-16-1 provided by Julian Leibowitz, Texas A&M University).
464 Bound primary antibodies were detected by an avidin-biotin immunoperoxidase technique

465 (Vector Laboratories) using 3, 3-diaminobenzidine as the substrate. Control slides from mock-
466 infected mice were stained in parallel. All slides were coded and read in a blinded manner by
467 the same investigator, as described previously with minor modifications (40).

468 H&E Sections were assessed for inflammation in the following manner: 0, none; 1, few
469 inflammatory cells; 2, organization of perivascular infiltrates; and 3, increasing severity of
470 perivascular cuffing and formation of microglial nodules, and represented in Table 1 (47).

471 **Quantification of histopathological sections**

472 The number of hepatic lesions were counted per section and averaged for each mouse at each
473 time point (both acute and chronic phase of inflammation). The functional scoring of the
474 inflammatory lesions in the liver was characterized as the Hepatic activity index (HAI). Degree
475 of activity was categorized as portal inflammation; Interphase hepatitis (Piecemeal necrosis);
476 Focal (Spotty) necrosis, apoptosis, and focal inflammation; and Confluent necrosis. Scores
477 from 0-6 were allotted for each category based on the modified Knodell's HAI, commonly
478 referred to as the Ishak system (69).

479 Image analysis was performed using the basic densitometric thresholding application of Fiji
480 (Image J, NIH Image, Scion Image) as described previously (48). Briefly, image analysis for
481 CD45 and CD11b stained sections was performed by capturing the images at the highest
482 magnification (4X-for brain, 10X-for spinal cord) such that the entire section (i.e., scan area)
483 can be visualized within a single frame. The RGB image was deconvoluted into three different
484 colours to separate and subtract the DAB-specific staining from the background H&E staining.
485 The perimeter of each brain and spinal cord tissue was digitally outlined, and the area was
486 calculated in μm^2 . A threshold value was fixed for each image to make sure that all antibody
487 marked cells are taken into consideration. The amount of CD45, and CD11b staining was
488 termed as the '% area of staining'.

489 To determine the area of demyelination, LFB-stained spinal cord cross-sections from each
490 mouse were chosen and analyzed using Fiji software (Image J 1.52g). The total perimeter of
491 the white matter regions in each cross-section was marked and calculated by adding together
492 the dorsal, ventral and anterior white matter areas in each section. Also, the total area of the
493 demyelinated regions was outlined and collated for each section separately. The percentage of
494 spinal cord demyelination per section per mouse was calculated.

495 **Gene Expression: RNA Isolation, Reverse transcription and quantitative Polymerase**
496 **chain reaction**

497 RNA was extracted from brain tissues (flash-frozen) of RSA59 infected CD4^{+/+} and CD4^{-/-} and
498 mock-infected mice (3 from each group at days 5, 10 and 15 p.i.) using the Trizol isolation
499 protocol following transcardial perfusion with DEPC treated PBS. The total RNA
500 concentration was measured using a NanoDrop ND-100 spectrophotometer. 1µg of RNA was
501 used to prepare cDNA using a High Capacity cDNA Reverse Transcription Kit (Applied
502 Biosystems). Quantitative Real-time PCR analysis was performed using DyNAmo Color Flash
503 SYBR Green qPCR kit (Thermo Scientific) in a Step One plus Real-time PCR system (Thermo
504 Fisher Scientific) under the following conditions: initial denaturation at 95°C for 7 min, 40
505 cycles of 95°C for 10 s, 60°C for 30 s, melting curve analysis at 60°C for 30 s. Reactions were
506 performed in triplicate. Sequences for the primers used are given in Table III. Relative
507 quantitation was achieved using the comparative threshold ($\Delta\Delta Ct$) method. mRNA expression
508 levels of target genes in RSA59 infected CD4^{+/+} and CD4^{-/-} mice were normalized with β -Actin
509 and expressed as relative fold change compared to their respective mock-infected controls.

510 **Ultra-structural studies and electron microscopy to characterize the preservation of**
511 **myelin and axons**

512 To characterize axonal blebbing, disruption of the myelin sheath, and axon-myelin coherence,
513 ultrastructural studies were carried out on the brains, brainstem and spinal cords of mice.
514 Infected CD4^{-/-}, CD4^{+/+} and CD4^{-/-} mock-infected mice were anesthetized and sacrificed at day
515 28 p.i. Mice were perfused with 4% PFA. Brains and spinal cords were harvested and fixed
516 overnight in 2% glutaraldehyde, post-fixed with 1% osmium tetroxide, and dehydrated in a
517 graded series of ethanol washes. For transmission electron microscopy, samples were flat
518 embedded in Poly-Bed 812 epoxy resin (Polysciences) and sectioned (500 nm) from the
519 lesional epicenter. Toluidine blue staining was performed for examination by light microscopy.
520 Ultrathin TEM sections (600 Å) were trimmed from the representative foci of interest from
521 toluidine blue-stained sections and mounted on 200 mesh copper grids, stained with uranyl
522 acetate and bismuth subnitrite, and viewed under a JEOL JEM 1010 electron microscope (40).

523 **Statistical Analyses**

524 The viral titer was calculated as plaque-forming units (PFU) based on the following formula =
525 (no. of plaques X dilution factor/ml/gram of tissue). Virus titer was expressed as log₁₀

526 PFU/gram of tissue. Quantitative RT-PCR data were presented as mean values \pm SEM. Values
527 were subjected to Two-Way ANOVA/Student's t-test analysis for calculating the significance
528 of differences between the means. Also, multiple comparisons were achieved by the Tukey test
529 and the Holm-Sidak test. All statistical analyses were done using GraphPad Prism 6 (La Jolla,
530 CA). A P-value of <0.05 was considered statistically significant.

531 **ACKNOWLEDGEMENTS**

532 This work was supported by the Department of Biotechnology [BT/PR
533 20922/MED/122/37/2016] research grant, India; Animal facility, University of Pennsylvania;
534 Histopathology core, Thomas Jefferson University, Philadelphia, USA; NIH grant EY015014;
535 Research to Prevent Blindness; and the F. M. Kirby Foundation. We thank IISER-Kolkata
536 animal facility for providing necessary support. We thank Ministry of Human Resource
537 Development (MHRD), India, Council of Scientific and Industrial Research (CSIR), India and
538 University Grants Commission (UGC), India for fellowships to DC, FS, AB and SK.

539 **DECLARATIONS**

540 **Ethics approval**

541 All experimental procedures and animal care and use were strictly regulated and reviewed in
542 accordance with good animal ethics approved by the Institutional Animal Care and Use
543 Committee at the Indian Institute of Science Education and Research Kolkata (AUP No.
544 IISERK/IAEC/AP/2017/15) and the University of Pennsylvania, Philadelphia, USA (IACUC
545 Protocol No. 804701). Experiments were performed following the guidelines of the Committee
546 for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), India and
547 the United States National Institutes of Health Office of Laboratory Animal Welfare Guide for
548 the Care and Use of Laboratory Animals, 8th Edition.

549 **Consent for publication**

550 Not Applicable

551 **Availability of data and materials**

552 The datasets used and/or analyzed during the current study will be made available from the
553 corresponding author on reasonable request.

554 **Author Contribution**

555 DC, FD and JDS designed and planned all the experiments. DC, and FS performed the
556 experiments. DC, FS, and JDS analyzed the data and wrote the manuscript. AB, SK, RK and
557 KD helped with the standardization of RNA experiments in the knockout mice. LK blindly
558 read the pathological samples. JDS, KS and LK participated in data analysis and data
559 interpretation. LK and KS were involved in critical revisions of the manuscript. JDS and KS
560 jointly supervised and reviewed this work.

561 **Competing interests**

562 The authors declare that they have no competing interests.

563 **REFERENCES**

- 564 1. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. 2010. Mechanisms Underlying
565 Inflammation in Neurodegeneration. *Cell* 140:918-934.
- 566 2. Waisman A, Liblau RS, Becher B. 2015. Innate and adaptive immune responses in the CNS. *The*
567 *Lancet Neurology* 14:945-955.
- 568 3. Prinz M, Priller J. 2017. The role of peripheral immune cells in the CNS in steady state and
569 disease. *Nature Neuroscience* 20:136-144.
- 570 4. Schetters STT, Gomez-Nicola D, Garcia-Vallejo JJ, Van Kooyk Y. 2018. Neuroinflammation:
571 Microglia and T Cells Get Ready to Tango. *Frontiers in immunology* 8:1905-1905.
- 572 5. McFarlin DE, McFarland HF. 1982. Multiple sclerosis (second of two parts). *The New England*
573 *journal of medicine* 307:1246-1251.
- 574 6. McFarlin DE, McFarland HF. 1982. Multiple sclerosis (first of two parts). *The New England*
575 *journal of medicine* 307:1183-1188.
- 576 7. Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. 1994. Increased frequency
577 of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in
578 peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. *The Journal of*
579 *experimental medicine* 179:973-984.
- 580 8. Martin R, McFarland HF. 1995. Immunological aspects of experimental allergic
581 encephalomyelitis and multiple sclerosis. *Critical reviews in clinical laboratory sciences*
582 32:121-182.
- 583 9. Steinman L. 1996. Multiple sclerosis: a coordinated immunological attack against myelin in
584 the central nervous system. *Cell* 85:299-302.
- 585 10. Sospedra M, Martin R. 2005. Immunology of multiple sclerosis. *Annual review of immunology*
586 23:683-747.
- 587 11. Kuchroo VK, Anderson AC, Waldner H, Munder M, Bettelli E, Nicholson LB. 2002. T cell
588 response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive
589 antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. *Annual*
590 *review of immunology* 20:101-123.
- 591 12. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T,
592 Kastelein RA, Cua DJ. 2005. IL-23 drives a pathogenic T cell population that induces
593 autoimmune inflammation. *The Journal of experimental medicine* 201:233-240.

- 594 13. Martin B, Hirota K, Cua DJ, Stockinger B, Veldhoen M. 2009. Interleukin-17-producing
595 gammadelta T cells selectively expand in response to pathogen products and environmental
596 signals. *Immunity* 31:321-330.
- 597 14. Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, Lira S, Uccelli A, Lanzavecchia
598 A, Engelhardt B, Sallusto F. 2009. C-C chemokine receptor 6-regulated entry of TH-17 cells into
599 the CNS through the choroid plexus is required for the initiation of EAE. *Nature immunology*
600 10:514-523.
- 601 15. Das Sarma J, Ciric B, Marek R, Sadhukhan S, Caruso ML, Shafagh J, Fitzgerald DC, Shindler KS,
602 Rostami A. 2009. Functional interleukin-17 receptor A is expressed in central nervous system
603 glia and upregulated in experimental autoimmune encephalomyelitis. *Journal of*
604 *neuroinflammation* 6:14-14.
- 605 16. Murphy AC, Lalor SJ, Lynch MA, Mills KHG. 2010. Infiltration of Th1 and Th17 cells and
606 activation of microglia in the CNS during the course of experimental autoimmune
607 encephalomyelitis. *Brain, Behavior, and Immunity* 24:641-651.
- 608 17. Li J, Zhao X, Hao H-W, Shaw MK, Tse HY. 2011. T cells that trigger acute experimental
609 autoimmune encephalomyelitis also mediate subsequent disease relapses and predominantly
610 produce IL-17. *Journal of neuroimmunology* 230:26-32.
- 611 18. Rostami A, Ciric B. 2013. Role of Th17 cells in the pathogenesis of CNS inflammatory
612 demyelination. *Journal of the neurological sciences* 333:76-87.
- 613 19. Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, Cua DJ, Ahlfors H, Wilhelm C, Tolaini M,
614 Menzel U, Garefalaki A, Potocnik AJ, Stockinger B. 2011. Fate mapping of IL-17-producing T
615 cells in inflammatory responses. *Nature immunology* 12:255-263.
- 616 20. Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlén C, Goverman J. 2001. A pathogenic role for
617 myelin-specific CD8(+) T cells in a model for multiple sclerosis. *The Journal of experimental*
618 *medicine* 194:669-676.
- 619 21. Sun D, Whitaker JN, Huang Z, Liu D, Coleclough C, Wekerle H, Raine CS. 2001. Myelin antigen-
620 specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice.
621 *Journal of immunology (Baltimore, Md : 1950)* 166:7579-7587.
- 622 22. Wagner CA, Roqué PJ, Mileur TR, Liggitt D, Goverman JM. 2020. Myelin-specific CD8+ T cells
623 exacerbate brain inflammation in CNS autoimmunity. *The Journal of clinical investigation*
624 130:203-213.
- 625 23. Lane TE, Liu MT, Chen BP, Asensio VC, Samawi RM, Paoletti AD, Campbell IL, Kunkel SL, Fox
626 HS, Buchmeier MJ. 2000. A central role for CD4(+) T cells and RANTES in virus-induced central
627 nervous system inflammation and demyelination. *Journal of virology* 74:1415-1424.
- 628 24. Wu GF, Dandekar AA, Pewe L, Perlman S. 2000. CD4 and CD8 T cells have redundant but not
629 identical roles in virus-induced demyelination. *Journal of immunology (Baltimore, Md : 1950)*
630 165:2278-2286.
- 631 25. Gagliano SA, Pouget JG, Hardy J, Knight J, Barnes MR, Ryten M, Weale ME. 2016. Genomics
632 implicates adaptive and innate immunity in Alzheimer's and Parkinson's diseases. *Annals of*
633 *clinical and translational neurology* 3:924-933.
- 634 26. González H, Pacheco R. 2014. T-cell-mediated regulation of neuroinflammation involved in
635 neurodegenerative diseases. *Journal of neuroinflammation* 11:201-201.
- 636 27. Browne TC, McQuillan K, McManus RM, O'Reilly J-A, Mills KHG, Lynch MA. 2013. IFN- γ
637 Production by amyloid β -specific Th1 cells promotes microglial activation and increases plaque
638 burden in a mouse model of Alzheimer's disease. *Journal of immunology (Baltimore, Md : 1950)*
639 190:2241-2251.
- 640 28. Zhang J, Ke K-F, Liu Z, Qiu Y-H, Peng Y-P. 2013. Th17 cell-mediated neuroinflammation is
641 involved in neurodegeneration of $\alpha\beta 1$ -42-induced Alzheimer's disease model rats. *PloS one*
642 8:e75786-e75786.
- 643 29. Saresella M, Piancone F, Tortorella P, Marventano I, Gatti A, Caputo D, Lunetta C, Corbo M,
644 Rovaris M, Clerici M. 2013. T helper-17 activation dominates the immunologic milieu of both

- 645 amyotrophic lateral sclerosis and progressive multiple sclerosis. *Clinical immunology*
646 (Orlando, Fla) 148:79-88.
- 647 30. Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O,
648 Alvarez-Fischer D, Callebert J, Launay J-M, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S. 2009.
649 Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse
650 model of Parkinson disease. *The Journal of clinical investigation* 119:182-192.
- 651 31. Beers DR, Henkel JS, Zhao W, Wang J, Appel SH. 2008. CD4+ T cells support glial
652 neuroprotection, slow disease progression, and modify glial morphology in an animal model
653 of inherited ALS. *Proceedings of the National Academy of Sciences of the United States of*
654 *America* 105:15558-15563.
- 655 32. Zheng C, Zhou X-W, Wang J-Z. 2016. The dual roles of cytokines in Alzheimer's disease: update
656 on interleukins, TNF- α , TGF- β and IFN- γ . *Translational neurodegeneration* 5:7-7.
- 657 33. Stohlman SA, Hinton DR, Parra B, Atkinson R, Bergmann CC. 2008. CD4 T Cells Contribute to
658 Virus Control and Pathology following Central Nervous System Infection with Neurotropic
659 Mouse Hepatitis Virus. 82:2130-2139.
- 660 34. Murray PD, Pavelko KD, Leibowitz J, Lin X, Rodriguez M. 1998. CD4(+) and CD8(+) T cells make
661 discrete contributions to demyelination and neurologic disease in a viral model of multiple
662 sclerosis. *Journal of Virology* 72:7320-7329.
- 663 35. Togo T, Akiyama H, Iseki E, Kondo H, Ikeda K, Kato M, Oda T, Tsuchiya K, Kosaka K. 2002.
664 Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases.
665 *Journal of neuroimmunology* 124:83-92.
- 666 36. Strachan-Whaley M, Rivest S, Yong VW. 2014. Interactions between microglia and T cells in
667 multiple sclerosis pathobiology. *Journal of interferon & cytokine research : the official journal*
668 *of the International Society for Interferon and Cytokine Research* 34:615-622.
- 669 37. Garber C, Soung A, Vollmer LL, Kanmogne M, Last A, Brown J, Klein RS. 2019. T cells promote
670 microglia-mediated synaptic elimination and cognitive dysfunction during recovery from
671 neuropathogenic flaviviruses. *Nature Neuroscience* 22:1276-1288.
- 672 38. Lavi E, Gilden DH, Wroblewska Z, Rorke LB, Weiss SR. 1984. Experimental demyelination
673 produced by the A59 strain of mouse hepatitis virus. *Neurology* 34:597-603.
- 674 39. Das Sarma J, Scheen E, Seo S-h, Koval M, Weiss SR. 2002. Enhanced green fluorescent protein
675 expression may be used to monitor murine coronavirus spread in vitro and in the mouse
676 central nervous system. *Journal of NeuroVirology* 8:381-391.
- 677 40. Das Sarma J, Kenyon LC, Hingley ST, Shindler KS. 2009. Mechanisms of Primary Axonal Damage
678 in a Viral Model of Multiple Sclerosis. *The Journal of Neuroscience* 29:10272-10280.
- 679 41. Stohlman SA, Weiner LP. 1981. Chronic central nervous system demyelination in mice after
680 JHM virus infection. *Neurology* 31:38-44.
- 681 42. Sutherland RM, Chua MM, Lavi E, Weiss SR, Paterson Y. 1997. CD4+ and CD8+ T cells are not
682 major effectors of mouse hepatitis virus A59-induced demyelinating disease. *Journal of*
683 *neurovirology* 3:225-228.
- 684 43. Shindler KS, Kenyon LC, Dutt M, Hingley ST, Das Sarma J. 2008. Experimental optic neuritis
685 induced by a demyelinating strain of mouse hepatitis virus. *Journal of virology* 82:8882-8886.
- 686 44. Houtman JJ, Fleming JO. 1996. Pathogenesis of mouse hepatitis virus-induced demyelination.
687 *Journal of neurovirology* 2:361-376.
- 688 45. Biswas K, Chatterjee D, Addya S, Khan RS, Kenyon LC, Choe A, Cohrs RJ, Shindler KS, Das Sarma
689 J. 2016. Demyelinating strain of mouse hepatitis virus infection bridging innate and adaptive
690 immune response in the induction of demyelination. *Clinical immunology (Orlando, Fla)* 170:9-
691 19.
- 692 46. Chatterjee D, Addya S, Khan RS, Kenyon LC, Choe A, Cohrs RJ, Shindler KS, Sarma JD. 2014.
693 Mouse hepatitis virus infection upregulates genes involved in innate immune responses. *PLoS*
694 *one* 9:e111351-e111351.

- 695 47. Kishore A, Kanaujia A, Nag S, Rostami AM, Kenyon LC, Shindler KS, Das Sarma J. 2013. Different
696 mechanisms of inflammation induced in virus and autoimmune-mediated models of multiple
697 sclerosis in C57BL6 mice. *BioMed research international* 2013:589048-589048.
- 698 48. Singh M, Kishore A, Maity D, Sunanda P, Krishnarjuna B, Vappala S, Raghothama S, Kenyon LC,
699 Pal D, Das Sarma J. 2019. A proline insertion-deletion in the spike glycoprotein fusion peptide
700 of mouse hepatitis virus strongly alters neuropathology. doi:10.1074/jbc.RA118.004418.
- 701 49. Zipp F, Aktas O. 2006. The brain as a target of inflammation: common pathways link
702 inflammatory and neurodegenerative diseases. *Trends in neurosciences* 29:518-527.
- 703 50. Aspelund A, Antila S, Proulx ST, Karlsten TV, Karaman S, Detmar M, Wiig H, Alitalo K. 2015. A
704 dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. *The*
705 *Journal of experimental medicine* 212:991-999.
- 706 51. Engelhardt B, Ransohoff RM. 2005. The ins and outs of T-lymphocyte trafficking to the CNS:
707 anatomical sites and molecular mechanisms. *Trends in immunology* 26:485-495.
- 708 52. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell
709 JW, Lee KS, Harris TH, Kipnis J. 2015. Structural and functional features of central nervous
710 system lymphatic vessels. *Nature* 523:337-341.
- 711 53. Kivisäkk P, Mahad DJ, Callahan MK, Trebst C, Tucky B, Wei T, Wu L, Baekkevold ES, Lassmann
712 H, Staugaitis SM, Campbell JJ, Ransohoff RM. 2003. Human cerebrospinal fluid central memory
713 CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin.
714 *Proceedings of the National Academy of Sciences of the United States of America* 100:8389-
715 8394.
- 716 54. Zhang J, Weiner HL, Hafler DA. 1992. Autoreactive T Cells in Multiple Sclerosis. *International*
717 *Reviews of Immunology* 9:183-201.
- 718 55. Raine CS. 1994. The Dale E. McFarlin memorial lecture: The immunology of the multiple
719 sclerosis lesion. *Annals of Neurology* 36:S61-S72.
- 720 56. Kaushansky N, Zhong M-C, Kerlero de Rosbo N, Hoeffberger R, Lassmann H, Ben-Nun A. 2006.
721 Epitope Specificity of Autoreactive T and B Cells Associated with Experimental Autoimmune
722 Encephalomyelitis and Optic Neuritis Induced by Oligodendrocyte-Specific Protein in SJL/J
723 Mice. *The Journal of Immunology* 177:7364.
- 724 57. Kaushansky N, Altmann DM, David CS, Lassmann H, Ben-Nun A. 2012. DQB1*0602 rather than
725 DRB1*1501 confers susceptibility to multiple sclerosis-like disease induced by proteolipid
726 protein (PLP). *Journal of Neuroinflammation* 9:29.
- 727 58. Panitch H, Haley A, Hirsch R, Johnson K. 1987. Exacerbations of Multiple Sclerosis in patients
728 treated with gamma Interferon. *The Lancet* 329:893-895.
- 729 59. Bernard CC. 1976. Experimental autoimmune encephalomyelitis in mice: genetic control of
730 susceptibility. *J Immunogenet* 3:263-74.
- 731 60. Miller SD, Vanderlugt CL, Begolka WS, Pao W, Yauch RL, Neville KL, Katz-Levy Y, Carrizosa A,
732 Kim BS. 1997. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope
733 spreading. *Nat Med* 3:1133-6.
- 734 61. Shemer A, Erny D, Jung S, Prinz M. 2015. Microglia Plasticity During Health and Disease: An
735 Immunological Perspective. *Trends in Immunology* 36:614-624.
- 736 62. Squarzoni P, Thion M, Garel S. 2015. Neuronal and microglial regulators of cortical wiring:
737 usual and novel guideposts. *Frontiers in Neuroscience* 9.
- 738 63. Prinz M, Priller J. 2014. Microglia and brain macrophages in the molecular age: from origin to
739 neuropsychiatric disease. *Nature Reviews Neuroscience* 15:300.
- 740 64. Biber K, Möller T, Boddeke E, Prinz M. 2015. Central nervous system myeloid cells as drug
741 targets: current status and translational challenges. *Nature Reviews Drug Discovery* 15:110.
- 742 65. Liddel SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, Münch
743 AE, Chung W-S, Peterson TC, Wilton DK, Frouin A, Napier BA, Panicker N, Kumar M, Buckwalter
744 MS, Rowitch DH, Dawson VL, Dawson TM, Stevens B, Barres BA. 2017. Neurotoxic reactive
745 astrocytes are induced by activated microglia. *Nature* 541:481.

- 746 66. Anderson MA, Burda JE, Ren Y, Ao Y, O'Shea TM, Kawaguchi R, Coppola G, Khakh BS, Deming
 747 TJ, Sofroniew MV. 2016. Astrocyte scar formation aids CNS axon regeneration. Nature
 748 532:195-200.
- 749 67. Rahemtulla A, Fung-Leung WP, Schilham MW, Kündig TM, Sambhara SR, Narendran A, Arabian
 750 A, Wakeham A, Paige CJ, Zinkernagel RM, Miller RG, Mak TM. 1991. Normal development and
 751 function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature
 752 353:180-184.
- 753 68. Podbielska M, Banik NL, Kurowska E, Hogan EL. 2013. Myelin recovery in multiple sclerosis:
 754 the challenge of remyelination. Brain sciences 3:1282-1324.
- 755 69. Goodman ZD. 2007. Grading and staging systems for inflammation and fibrosis in chronic liver
 756 diseases. Journal of hepatology 47:598-607.

757

758 **FIGURE LEGENDS**

759 **Fig. 1. Temporal immune cell kinetics in the brains of RSA59 infected mice.** Results from
 760 flow cytometric analysis of the migration of inflammatory cells and CNS resident cells from
 761 the RSA59 infected mice has been summarized in the schematic diagram. The diagram
 762 represents the differential infiltration of total myeloid (neutrophils, macrophage/monocytes and
 763 microglia) and lymphoid (CD4, CD8 and NKT) cell populations during days 3, 5, 7, 10, 16 and
 764 30 p.i. Respective peaks show highest infiltration at times post infection. ScaleArbitrary.

765 **Fig. 2. Absence of CD4 causes no significant pathology in the mock infected mice.** CD4^{+/+}
 766 and CD4^{-/-} mice were infected with with an uninfected cell lysate (PBS+0.075% BSA). 5-
 767 micron thick liver,brain and spinal cord sections were stained with H&E and CD45 for routine
 768 histopathological studies. No inflammation was observed in CD4^{+/+} and CD4^{-/-} mice tissues.
 769 Data are represented from 3 independent biological replicates. Scale bars= 50 microns

770 **Fig.3 Absence of CD4 shows no significant alterations in RSA59 induced Liver pathology.**
 771 CD4^{+/+} and CD4^{-/-} mice were infected with RSA59 and 5-micron thick liver sections were
 772 stained with H&E for routine morphological studies. a) Both CD4^{+/+} and CD4^{-/-} mice showed
 773 similar features of necrotic/non-necrotic hepatitis. Hepatic Activity Index was calculated
 774 according to Ishak's Score as described in materials and methods and plotted (b). c) The
 775 average number of hepatic lesions were counted per section from each mouse, combined results
 776 were tabulated. Liver sizes and cross-sectional areas were comparable in both CD4^{+/+} and CD⁻
 777 ^{-/-} mice. Data are represented from 5 independent biological experiments.

778 **Fig.4 Absence of CD4 demonstrates no significant changes in encephalomyelitis upon**
 779 **RSA59 induced acute infection.** a, b) At day 6 p.i., sections of brain (panel a) and spinal cord

780 (panel b) from CD4^{+/+} mice and CD4^{-/-} mice were stained with H&E and
781 immunohistochemically for LCA (leucocyte common antigen). Boxed areas are shown at
782 higher magnification below the corresponding brain midsagittal sections (panel a) or cross
783 sections of spinal cord (panel b). The arrows in the zoomed sections mark characteristic
784 perivascular cuffing and microglial nodule formation mediated by infiltrating inflammatory
785 cells in the H&E-stained sections which correspond to immunoreactive leukocytes and
786 microglia/macrophages in the CD45 immunohistochemically stained sections. Scale bars of
787 midsagittal brain sections represent 1000 microns whereas they represent 100 microns in the
788 higher magnification images shown below. Scale bars of spinal cord cross sections represent
789 200 microns whereas they represent 50 microns in the higher magnification images shown
790 below. Quantification of the intensity of staining is plotted in a scatter diagram. Statistical
791 analysis was performed using Student's t-test and Welch correction. Data are represented from
792 5 independent biological experiments.

793 **Fig.5 Absence of CD4 resulted in a significant reduction of CD11b positive**
794 **microglia/macrophages in the brain and spinal cords during RSA59 induced acute**
795 **infection.** At day 6 p.i., sections of brain and spinal cord from CD4^{+/+} mice and CD4^{-/-} mice
796 were immunohistochemically stained for CD11b (macrophage/microglia activation marker).
797 Boxed areas are shown at higher magnification below the corresponding brain midsagittal
798 sections (upper panel) or cross sections of spinal cord (lower panel). Arrows mark
799 microglia/macrophages in the in the CD11b immunohistochemically stained sections. Scale
800 bars of midsagittal brain sections represent 500 microns whereas they represent 200 microns
801 in the higher magnification images shown below. Scale bars of spinal cord cross sections
802 represent 500 microns whereas they represent 200 microns in the higher magnification images
803 shown below. Quantification of the intensity of staining is plotted in a scatter diagram.
804 Statistical analysis was performed using Student's t-test and Welch correction. ***p<0.001;
805 ****p<0.0001. Data are represented from 5 independent biological experiments. Error bar
806 represents SEM.

807 **Fig.6 Absence of CD4 results in severe poliomyelitis and dorsal root ganglionic**
808 **inflammation during acute RSA59 infection.** Sections of CD4^{+/+} and CD4^{-/-} mouse spinal
809 cords were stained with H&E and immunohistochemically with anti-CD45. There is increased
810 inflammation of the gray matter (poliomyelitis) and dorsal root ganglia in CD4^{-/-} as compared

811 to CD4^{+/+} mice. Mock-infected mice showed no inflammation. All scale bars indicate 90µm.
812 N=5.

813 **Fig.7 Absence of CD4 results in reduced viral clearance and altered expression of**
814 **antiviral effector genes.** a) Whole-brain lysates from CD4^{+/+} and CD4^{-/-} mice at days 5, 10
815 and 15 p.i. were subjected to comparative viral plaque assays on confluent monolayers of L2
816 cells. Each time point represents the mean titer for three mice. Titers are expressed as log10
817 PFU per gram of tissue. b) The relative abundance of transcripts corresponding to viral N-gene
818 was compared using qRT-PCR in the CD4^{+/+} and CD4^{-/-} infected mouse brains at days 5, 10
819 and 15 p.i. c) Anti-N immunohistochemistry revealed the differential in-situ distribution of
820 viral antigen in the representative anatomical regions (between brain stem and deep cerebellar
821 white matter) of mock-infected CD4^{+/+}; and RSA59 infected CD4^{+/+} and CD4^{-/-} mice at days
822 6 and 30 p.i.. Scale bar 100µm (4X) and 50µm (40X). Relative gene expression of IFN γ (d),
823 CXCL10 (e), TNF α (f) and CCL5 (g) at days 5, 10 and 15 p.i. were analyzed by qRT-PCR and
824 compared between CD4^{+/+} and CD4^{-/-} mice. qRT-PCR results were expressed as fold mean \pm
825 SEM. Statistical analysis of the data represented in panels a, b, d, e, f, and g) was calculated
826 using Two-way ANOVA, and multiple comparison was achieved by Hom's Sidak; *p<0.05;
827 **p<0.01; ***p<0.001; ****p<0.0001. Data are represented from 3 independent biological
828 experiments, N=3, 3 technical replicates each.

829 **Fig.8 Absence of CD4 leads to severe chronic inflammatory demyelination and axonal**
830 **loss.** a) Cross-sections of CD4^{+/+} and CD4^{-/-} mouse spinal cords were analyzed for the presence
831 of inflammatory lesions by H&E, demyelination by LFB, and inflammatory cells by anti-CD45
832 and anti-CD11b (microglia/macrophages) immunohistochemistry. Boxed areas are shown at
833 higher magnification to right of the corresponding spinal cord cross sections. Arrows mark
834 demyelinating plaques on the LFB stained sections, infiltrating inflammatory cells in the H&E
835 stained sections, and immunoreactive leukocytes and microglia/macrophages in the CD45 and
836 CD11b immunohistochemically stained sections respectively. Scale bars of spinal cord cross
837 sections represent 200 microns whereas they represent 50 microns in the higher magnification
838 images. Levels of demyelination and inflammation are plotted in a scatter diagram (b, c, d).
839 Statistical significance was calculated by unpaired Student's t-test and Welch correction.
840 ***p< 0.001; ****p<0.0001). Data are represented from 4-5 independent biological
841 experiments. Error bar represents SEM.

842 **Fig.9 Absence of CD4 causes abnormal bulbar (brainstem) vacuolation and neuronal loss**
843 **in RSA59 infected brains at day 30 p.i.** a) Serial sagittal sections of brains from both CD4^{+/+}
844 and CD4^{-/-} mice were analyzed for inflammation at day 30 p.i. by H&E and
845 immunohistochemically by CD45 and CD11b. Boxed areas are shown at higher magnification
846 below the corresponding brain midsagittal sections. Arrows mark infiltrating inflammatory
847 cells in the H&E stained sections, and immunoreactive leukocytes and microglia/macrophages
848 in the CD45 and CD11b immunohistochemically stained sections respectively. Scale bars of
849 spinal cord cross sections represent 200 microns whereas they represent 50 microns in the
850 higher magnification images. Quantification of inflammation was performed for CD45 (b) and
851 CD11b (c) staining. The level of significance was calculated by unpaired Student's t-test and
852 Welch correction, ****p<0.0001). Error bar represents SEM. Data are represented from 4-5
853 independent biological experiments.

854 **Fig. 10. Absence of CD4 causes no alteration in the axon-myelin coherence in the brain**
855 **stem and spinal cord of mock infected mice.** Toluidine blue stained sections of
856 glutaraldehyde fixed, epoxy resin embedded sections (500 nm thick) from mock infected CD4⁻
857 ^{-/-} mouse brain stem (A, B) and spinal cord (C, D). A. Gray and white matter of brain stem.
858 Arrows mark bundles of intact myelinated fibres. Asterisks mark the neuronal nuclei. Original
859 magnification – 400X. B. Brain stem white matter. Original magnification - 1000X. C.
860 Spinal cord cross section. Original magnification 40X. Posterior columns in boxed area are
861 further magnified in D. Original magnification 1000X. White and gray matter in both the
862 brain stem and spinal cord show no evidence of inflammation, demyelination or cellular injury.

863 **Fig.11 Absence of CD4 results in severe spinal cord axonal injury upon RSA59 infection**
864 **at the chronic stage.** a and b: Toluidine blue-stained sections. a) Posterior columns (200X)
865 and b) (1000X) demonstrate clusters of degenerating axons. Arrows - degenerating axons,
866 asterixes - swollen myelin sheaths. c and d: Corresponding electron microscopy. c) Swollen
867 myelin sheaths with loss of axoplasm (7,500X). d) Cluster of degenerating axons with
868 collapsed myelin sheaths (10,000X). The arrow shows the corresponding area on the toluidine
869 blue-stained section. Scale bar represents 2 microns. Data are represented from 3 independent
870 biological experiments.

871 **Fig.12 qRT-PCR analysis of IL-6, IL-10, CD86, Btk and CD163 reveals an inflammatory**
872 **state in the brains of RSA59 infected CD4^{-/-} mice.** Quantitative PCR analysis of IL-6 (a) IL-
873 10 (b); CD86 (c); Btk (d); CD163 (e) analysis was performed in RSA59 infected CD4^{+/+} and

874 CD4^{-/-} mouse brains at days 5, 10 and 15. Data are represented from 3 independent biological
 875 experiments, N=3, 3 technical replicates each. Statistical analysis was performed by Two-way
 876 ANOVA, Hom Sidak's multiple comparison test; **p<0.01; ***p<0.001; ****p<0.0001. Error
 877 bar represents SEM.

878 **Table I. Average Inflammation score in RSA59-infected CD4^{+/+} and CD4^{-/-} mouse brain**
 879 **(47)**

	No. of mice	No. of sections	% mice with inflammation n	Mean score of Inflammation (mean ± SEM)
Acute phase RSA59 CD4 ^{+/+}	4	08	100 %	1.8±0.322
Chronic phase RSA59 CD4 ^{+/+}	5	10	100 %	1.4±0.163
Acute phase RSA59 CD4 ^{-/-}	4	08	100%	2.0±0.189
Chronic Phase RSA59 CD4 ^{-/-}	4	10	100%	2.5±0.189

880 Significant difference was observed only at the chronic phase of infection between CD4^{+/+}
 881 and CD4^{-/-} brains (***p=0.0004)

882 **Table II. Average Inflammation score in RSA59-infected CD4^{+/+} and CD4^{-/-} mouse**
 883 **spinal cord (47)**

	No. of mice	No. of sections	% mice with inflammation n	Mean score of Inflammation (mean ± SEM)
Acute phase RSA59 CD4 ^{+/+}	3*	20	80 %	0.6±0.112
Chronic phase RSA59 CD4 ^{+/+}	5	30	100 %	0.76±0.114
Acute phase RSA59 CD4 ^{-/-}	4	20	100%	1.1±0.143
Chronic Phase RSA59 CD4 ^{-/-}	4	20	100%	1.05±0.05

884 *1 mouse was an outlier; it did not get infected.

885 **Table III. List of Primers**

Gene	Forward 5'-3'	Reverse 5'-3'
CD86	GGCTCAAAACATAAGCCTGA	CCCATGTCCTTGATCTGAAC
CD163	GAGACACACGGAGCCATCAA	TGGACAAACCTTTTACAACCA GG
IFN γ	GTCTCTTCTTGGATATCTGGAG GAACT	GTAGTAATCAGGTGTGATTCA ATGACGC
TNF α	CTGTAGCCCACGTCGTAGC	TTGAGATCCATGCCGTTG
CCI5	CCA ATC TTG CAG TCG TGT TTG T	CAT CTC CAA ATA GTT GAT GTA TTC TTG AAC
CXCL10	GACGGTCCGCTGCAACTG	CTTCCCTATGGCCCTCATTCT
Btk1	ACAGCAGAACACATTGCTCA	GGGAACTCCTCAGGAAACAT
IL12 p40	GGAAGCACGGCAGCAGAATA	AACTTGAGGGAGAAGTAGGAA TGG
IL6	AGTTGCCTTCTTGGGACTGA	TCCACGATTTCCCAGAGAAC
IL10	AGTGGAGCAGGTGAAGAGTG	TTCGGGAGAGGTACAAACG
Anti -N	AGGATAGAAGTCTGTTGGCTCA	GAGAGAAGTTAGCAAGGTCCT ACG
GAPDH	GCCCCTTCTGCCGATGC	CTTCCAGAGGGGCCATCC
B- Actin	CTTCTACAATGAGCTGCGTGTG	GGTCTCAAACATGATCTGG

886

887


888

889

890

891

Chakravarty et. al., Fig. 1



892

893

894

895

896

897

898


899

900

901


902

903



904

905



906

907

908

909

910

911

912

913

914

915


916

917

918

919


Chakravarty et. al., Fig. 4



920

921

922



923

924

925

926

927


928

929

930

931

Chakravarty et. al., Fig. 6



932

933

934

935

936

937


938

939

940

941

Chakravarty et. al., Fig. 7





942

943

944

945






946

947

948

Chakravarty et. al., Fig. 9




949

950

951

Chakravarty et al., Fig. 10



952

953

954

955

956

957

958


959

960

961

962


Chakravarty et al., Fig. 11



963

964

965



966

967

968

969

970

971

972

973

974

975

976

977